Clinical trials: Psychotic Symptoms
Severe Mental Disorder, Obesity
Health Education Programme Through Physical Exercise for People With Severe Mental Disorders
The goal of this clinical trial is to [learn about, test, compare etc.] in individuals with severe mental disorders and obesity comorbid.
- Trial name
- HEPPE-PSMI (NCT06069739)
- Testing
- Guided physical activity, Standard physical activity
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Schizophrenia, Psychotic Disorders
Theta Burst Transcranial Magnetic Stimulation as Treatment for Auditory Verbal Hallucinations
Auditory verbal hallucinations (AVH) are a characterising symptom of schizophrenia. In the majority of patients, these AVH respond well to antipsychotic medication.
- Trial name
- NCT01512290
- Testing
- Theta Burst Transcranial Magnetic Stimulation
- Where
- Netherlands
- Volunteers
- 71 people
- Sponsor
- UMC Utrecht
Schizophrenia
A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)
This randomized, multi-center double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in patients with sub-optimally controlled symptoms of schizophrenia.
- Trial name
- NCT01235559
- Testing
- bitopertin [RO4917838] level 1, bitopertin [RO4917838] level 2
- Where
- 90 sites in United States, Bulgaria and 5 more
- Volunteers
- 604 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia and Related Disorders
An Extension Protocol for Patients Who Previously Completed the TMS Pilot Study
This is an open-label extension study to continue to evaluate the safety, tolerability and efficacy of the Repetitive Transcranial Magnetic Stimulation (rTMS) in subjects with schizophrenia or schizoaffective disorder who…
- Trial name
- NCT05526833
- Testing
- Repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Columbia University
Schizophrenia
Promoting Activity and Cognitive Enrichment in Schizophrenia (PACES)
This project will conduct a confirmatory efficacy trial of two novel psychosocial interventions, Cognitive Enhancement Therapy and Enriched Supportive Therapy, for the treatment of persistent negative symptoms in schizophrenia.
- Trial name
- NCT04143126
- Testing
- Cognitive Enhancement Therapy, Enriched Supportive Therapy
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Pittsburgh
Schizophrenia
Evaluation of the H1-coil Deep TMS in the Treatment of Negative Symptoms and Cognitive Deficit in Schizophrenia
The study evaluates the feasibility of using a 4 week stimulation protocol with the deep TMS H-coils for the treatment of negative symptoms and cognitive deficit in schizophrenia patients
- Trial name
- NCT00445926
- Testing
- deep TMS H-coil
- Where
- Israel
- Sponsor
- Shalvata Mental Health Center
Organic Brain Syndrome, Nonpsychotic, Neurocognitive Disorders
Intranasal Inhalations of Bioactive Factors Produced by M2 Macrophages in Patients With Organic Brain Syndrome
The investigators have designed an innovative proof-of-concept trial designed to provide data as to whether the treatment/rehabilitation efficacy and functional outcome of patients with organic brain syndrome are improved with…
- Conditions
- Organic Brain Syndrome, Nonpsychotic, Neurocognitive Disorders, Mental Disorder, Organic, Delirium, Dementia, Amnestic, Cognitive Disorders
- Trial name
- NCT02957123
- Testing
- Intranasal auto-M2-BFs
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Russian Academy of Medical Sciences
Schizophrenia, Exercise
Baduanjin Versus Brisk Walking for Cognition in Schizophrenia
The current study intends to recruit participants with schizophrenia for the practice of Baduanjin, brisk walking, and health education after enrollment. The study also including a maintenance program.
- Conditions
- Schizophrenia, Exercise, Condition
- Trial name
- NCT06226779
- Testing
- Baduanjin exercsie, Brisk walking, Health education
- Where
- Taiwan
- Volunteers
- 63 people
- Sponsor
- Chang Gung Memorial Hospital
Schizophrenia, Schizoaffective Disorder
Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia
Withania somnifera (WSE; Ashwagandha in Ayurveda) extracts have been used as an adaptogen or to build resistance to stress or diseases in indigenous medical systems in India for centuries.
- Trial name
- NCT01793935
- Testing
- Sensoril®
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- K.N. Roy Chengappa
Major Depressive Disorder, Psychotic Disorders
An International Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00128505
- Testing
- Mifepristone
- Where
- 19 sites in Bulgaria, Croatia and 2 more
- Volunteers
- 104 people
- Sponsor
- Corcept Therapeutics
Pain, Schizophrenia
Pain and Schizophrenia
The aim of the investigators project is to explore the mechanisms of pain insensitivity in patients with schizophrenia, in order to prevent its invalidating consequences.
- Trial name
- NCT01244542
- Testing
- unpleasant stimuli
- Where
- 5 sites in France
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- University Hospital, Strasbourg, France
Alzheimer's Disease Psychosis
ACP-204 in Adults With Alzheimer's Disease Psychosis
This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies in patients with ADP Substudy 1 (Phase 2) will evaluate efficacy and dose…
- Trial name
- NCT06159673
- Testing
- ACP-204
- Where
- 154 sites in United States, Brazil and 10 more
- Volunteers
- 1,074 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Bipolar I Disorder, Bipolar II Disorder
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
The goal of this clinical trial is to identify the specific characteristics (phenotypes) that may be useful to help select the right medication for weight loss, and to study the effect of individualized guided medication in…
- Conditions
- Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder, Obesity
- Trial name
- OBOE-Mayo (NCT07213466)
- Testing
- Group Therapy Program, semaglutide, Phentermine-Topiramate
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Schizophrenia, Negative Symptoms
Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia
Negative symptoms and cognitive dysfunction in schizophrenia (CDS) are core features of schizophrenia. These negative symptoms and cognitive deficits have a devastating impact on the function, employment, and social interactions…
- Conditions
- Schizophrenia, Negative Symptoms, Cognitive Dysfunction
- Trial name
- NCT01488929
- Testing
- TC-5619
- Where
- 64 sites in United States, Hungary and 4 more
- Volunteers
- 603 people
- Sponsor
- Targacept Inc.
Schizophrenia, Psychotic Disorders
Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia
The purpose of this study is to compare the effectiveness of two antipsychotic medications, Risperdal® Consta® versus Abilify®, over a 2-year treatment period in the long-term maintenance of patients with schizophrenia.
- Trial name
- NCT00299702
- Testing
- Abilify, Risperidal Consta
- Volunteers
- 355 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Treatment Resistant Depression (TRD)
Treatment Resistance in Psychiatric Disorders: the Search for Biological Markers Predictive of Response to Treatment
The disruption of immune system is a key candidate in the pathogenesis of psychiatric disorders, especially those resistant to traditional treatments.
- Conditions
- Schizophrenia, Treatment Resistant Depression (TRD), Bipolar Disorder (BD), Catatonia
- Trial name
- BIO-INM (NCT07741981)
- Testing
- Blood sampling, lumbar puncture, stool sampling, skin microbiopsy and psychometrics scales
- Where
- France
- Volunteers
- 700 people
- Sponsor
- Centre Hospitalier St Anne
Dyskinesia, Schizophrenia
Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
Tardive dyskinesia is a common complication of conventional antipsychotic treatment in subjects with schizophrenia. This study investigates whether the addition of the omega-3 fatty acid, ethyl-eicosapentaenoic acid (EPA) to…
- Trial name
- NCT00114595
- Testing
- eicosapentaenoic acid
- Where
- South Africa
- Volunteers
- 84 people
- Sponsor
- University of Stellenbosch
Methamphetamine Use Disorder, Methamphetamine-induced Psychosis
α-N-acetylgalactosaminidase in Methamphetamine Psychosis
This cross-sectional observational cohort study examined serum α-N-acetylgalactosaminidase levels in methamphetamine use disorder (MUD), methamphetamine-induced psychotic disorder (MP), and healthy control (HC) groups.
- Trial name
- NCT07434401
- Where
- Turkey (Türkiye)
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Elazığ Mental Health and Diseases Hospital
Neuropsychiatric Symptom
Dissecting Immunological and Autoimmune Mechanisms of Neuropsychiatric Diseases
The goal of this observational cohort study is to investigate the role of immune system in neuropsychiatric symptoms (NPS) and to identify immunological biomarkers that may improve the diagnosis, prognosis, and future treatment…
- Trial name
- DIAMOND (NCT07791212)
- Where
- 2 sites in United Kingdom
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- King's College London
Schizophrenia Relapse, Schizophrenia
Feasibility and Acceptability of a Smartphone App to Assess Early Warning Signs of Psychosis Relapse
About 1 in 100 people will experience an episode of psychosis. Some people will only experience one 'psychotic episode' and about a quarter of people make a full recovery.
- Conditions
- Schizophrenia Relapse, Schizophrenia, Schizo Affective Disorder, Psychotic Disorders
- Trial name
- ExPRESS:2 (NCT03558529)
- Volunteers
- 27 people
- Sponsor
- Manchester Academic Health Science Centre
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.